InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
Primocin® | Directed Differentiation of Murine and Human Small Intestinal Organoids Towar... | 2023 | Methods Mol Biol. | Martinez-Silgado A. et al. | DOI: 10.1007/978-1-0716-3076-1_9 |
Plasmocin® - Mycoplasma Elimination Reagent | The pro-inflammatory signature of lipopolysaccharide in spontaneous contracti... | 2023 | J Cell Mol Med. | Scharmacher J. et al. | DOI: 10.1111/jcmm.17805 |
Plasmocin® - Mycoplasma Elimination Reagent | The oncogenic function of PLAGL2 is mediated via ASCL2 and IGF2 and a Wnt-ind... | 2023 | Am J Physiol Gastrointest Liver Physiol. | Fischer A.D. et al. | DOI: 10.1152/ajpgi.00058.2022 |
QUANTI-Blue™ | Binding, Neutralization and Internalization of the Interleukin-13 Antibody, L... | 2023 | Dermatol Ther (Heidelb) | Okragly A.J. et al. | DOI: 10.1007/s13555-023-00947-7 |
IL-4 & IL-13 Reporter HEK 293 Cells | Binding, Neutralization and Internalization of the Interleukin-13 Antibody, L... | 2023 | Dermatol Ther (Heidelb) | Okragly A.J. et al. | DOI: 10.1007/s13555-023-00947-7 |
Anti-murine TLR2 (clone T2.5) Detection and Neutralizing mAb | Microglial cell response to experimental periodontal disease. | 2023 | J Neuroinflammation | Almarhoumi R. et al. | DOI: 10.1186/s12974-023-02821-x |
ODN 1826 - TLR9 ligand | Microglial cell response to experimental periodontal disease. | 2023 | J Neuroinflammation | Almarhoumi R. et al. | DOI: 10.1186/s12974-023-02821-x |
ODN 2088 | Microglial cell response to experimental periodontal disease. | 2023 | J Neuroinflammation | Almarhoumi R. et al. | DOI: 10.1186/s12974-023-02821-x |
LTA-SA | Microglial cell response to experimental periodontal disease. | 2023 | J Neuroinflammation | Almarhoumi R. et al. | DOI: 10.1186/s12974-023-02821-x |
Primocin® | Protocol for generating airway organoids from 2D air liquid interface-differe... | 2023 | STAR Protoc. | Rodenburg L.W. et al. | DOI: 10.1016/j.xpro.2023.102337 |
CL429 VacciGrade™ | Dual pattern recognition receptor ligands CL401, CL413, and CL429 as adjuvant... | 2023 | Virology | Gosavi M. et al. | DOI: 10.1016/j.virol.2023.06.001 |
CL401 VacciGrade™ | Dual pattern recognition receptor ligands CL401, CL413, and CL429 as adjuvant... | 2023 | Virology | Gosavi M. et al. | DOI: 10.1016/j.virol.2023.06.001 |
CL413 VacciGrade™ | Dual pattern recognition receptor ligands CL401, CL413, and CL429 as adjuvant... | 2023 | Virology | Gosavi M. et al. | DOI: 10.1016/j.virol.2023.06.001 |
LPS-EB (LPS from E. coli O111:B4) | DNA methylation and gene expression changes in mouse mammary tissue during su... | 2023 | Epigenetics | Ivanova E. et al. | DOI: 10.1080/15592294.2023.2215633 |
Zeocin® | Central repeat fragment of reelin leads to active reelin intracellular signal... | 2023 | Cell Signal | Li Q. et al. | DOI: 10.1016/j.cellsig.2023.110763 |
MPLA Synthetic | Effect of Glycosylation on Self-Assembly of Lipid A Lipopolysaccharides in Aq... | 2023 | Langmuir | Castelletto V. et al. | DOI: 10.1021/acs.langmuir.3c00828 |
FLA-PA Ultrapure | Bronchial epithelial cells release inflammatory markers linked to airway infl... | 2023 | World Allergy Organ J. | Losol P. et al. | DOI: 10.1016/j.waojou.2023.100786 |
Zeocin® | Expression of Human β-defensin 2 (hBD-2) in Pichia Pastoris and Investigation... | 2023 | Protein J. | Çobanoğlu Ş. et al. | DOI: 10.1007/s10930-023-10130-8 |
Normocin® - Antimicrobial Reagent | PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-... | 2023 | J Mammary Gland Biol Neoplasia | Amante R.J. et al. | DOI: 10.1007/s10911-023-09539-9 |
RAW-Blue™ Cells | The Potency of Cowpea Mosaic Virus Particles for Cancer In Situ Vaccination I... | 2023 | Mol Pharm. | Jung E. et al. | DOI: 10.1021/acs.molpharmaceut.3c00214 |